NBIX
Price
$135.43
Change
+$0.15 (+0.11%)
Updated
Aug 22 closing price
Capitalization
13.43B
72 days until earnings call
SBFM
Price
$1.40
Change
-$0.02 (-1.41%)
Updated
Aug 22 closing price
Capitalization
6.38M
One day until earnings call
Interact to see
Advertisement

NBIX vs SBFM

Header iconNBIX vs SBFM Comparison
Open Charts NBIX vs SBFMBanner chart's image
Neurocrine Biosciences
Price$135.43
Change+$0.15 (+0.11%)
Volume$547.98K
Capitalization13.43B
Sunshine Biopharma
Price$1.40
Change-$0.02 (-1.41%)
Volume$18.89K
Capitalization6.38M
NBIX vs SBFM Comparison Chart in %
Loading...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SBFM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NBIX vs. SBFM commentary
Aug 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBIX is a Buy and SBFM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 25, 2025
Stock price -- (NBIX: $135.43 vs. SBFM: $1.40)
Brand notoriety: NBIX and SBFM are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: NBIX: 61% vs. SBFM: 17%
Market capitalization -- NBIX: $13.43B vs. SBFM: $6.38M
NBIX [@Pharmaceuticals: Generic] is valued at $13.43B. SBFM’s [@Pharmaceuticals: Generic] market capitalization is $6.38M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $69.41B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBIX’s FA Score shows that 0 FA rating(s) are green whileSBFM’s FA Score has 0 green FA rating(s).

  • NBIX’s FA Score: 0 green, 5 red.
  • SBFM’s FA Score: 0 green, 5 red.
According to our system of comparison, SBFM is a better buy in the long-term than NBIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBIX’s TA Score shows that 7 TA indicator(s) are bullish while SBFM’s TA Score has 3 bullish TA indicator(s).

  • NBIX’s TA Score: 7 bullish, 2 bearish.
  • SBFM’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, NBIX is a better buy in the short-term than SBFM.

Price Growth

NBIX (@Pharmaceuticals: Generic) experienced а +1.90% price change this week, while SBFM (@Pharmaceuticals: Generic) price change was -6.03% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +60.15%. For the same industry, the average monthly price growth was +10.62%, and the average quarterly price growth was +74.68%.

Reported Earning Dates

NBIX is expected to report earnings on Nov 04, 2025.

SBFM is expected to report earnings on Aug 25, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+60.15% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.4B) has a higher market cap than SBFM($6.38M). NBIX has higher P/E ratio than SBFM: NBIX (40.07) vs SBFM (0.00). NBIX YTD gains are higher at: -0.784 vs. SBFM (-53.333). NBIX has higher annual earnings (EBITDA): 557M vs. SBFM (-6.19M). NBIX has more cash in the bank: 976M vs. SBFM (10.3M). SBFM has less debt than NBIX: SBFM (929K) vs NBIX (439M). NBIX has higher revenues than SBFM: NBIX (2.51B) vs SBFM (36.3M).
NBIXSBFMNBIX / SBFM
Capitalization13.4B6.38M210,097%
EBITDA557M-6.19M-8,993%
Gain YTD-0.784-53.3331%
P/E Ratio40.070.003,978,952%
Revenue2.51B36.3M6,915%
Total Cash976M10.3M9,476%
Total Debt439M929K47,255%
FUNDAMENTALS RATINGS
NBIX vs SBFM: Fundamental Ratings
NBIX
SBFM
OUTLOOK RATING
1..100
2663
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
40
Fair valued
PROFIT vs RISK RATING
1..100
82100
SMR RATING
1..100
5896
PRICE GROWTH RATING
1..100
5387
P/E GROWTH RATING
1..100
6987
SEASONALITY SCORE
1..100
6550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SBFM's Valuation (40) in the null industry is somewhat better than the same rating for NBIX (73) in the Biotechnology industry. This means that SBFM’s stock grew somewhat faster than NBIX’s over the last 12 months.

NBIX's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as SBFM (100) in the null industry. This means that NBIX’s stock grew similarly to SBFM’s over the last 12 months.

NBIX's SMR Rating (58) in the Biotechnology industry is somewhat better than the same rating for SBFM (96) in the null industry. This means that NBIX’s stock grew somewhat faster than SBFM’s over the last 12 months.

NBIX's Price Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for SBFM (87) in the null industry. This means that NBIX’s stock grew somewhat faster than SBFM’s over the last 12 months.

NBIX's P/E Growth Rating (69) in the Biotechnology industry is in the same range as SBFM (87) in the null industry. This means that NBIX’s stock grew similarly to SBFM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBIXSBFM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
61%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
67%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 14 days ago
59%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
57%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SBFM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ETEC23.511.05
+4.69%
iShares Breakthrough Envirtl Sol ETF
SMIG30.190.56
+1.89%
Bahl & Gaynor Sm/Md Cp Inc Gr ETF
SPTE31.780.58
+1.87%
SP Funds S&P Global Technology ETF
PATN24.630.40
+1.65%
PACER FDS TR
FLV74.841.03
+1.40%
American Century Foc Lrg Cp Val ETF

SBFM and

Correlation & Price change

A.I.dvisor tells us that SBFM and ELAN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
-1.41%
ELAN - SBFM
30%
Poorly correlated
+2.40%
TLRY - SBFM
29%
Poorly correlated
+3.60%
AQST - SBFM
27%
Poorly correlated
+1.79%
CGC - SBFM
26%
Poorly correlated
+2.42%
NBIX - SBFM
25%
Poorly correlated
+0.11%
More